Chemical Compounds for Treating Hepatitis C Virus

A patent describing specific chemical structures designed to stop the Hepatitis C virus from replicating in humans.

What it covers

This patent defines a series of chemical structures, specifically compounds containing benzimidazolyl and heteroaryl rings, that act as antiviral agents. These molecules are engineered to interfere with the life cycle of the Hepatitis C virus (HCV). By administering these compounds, as described in claims 16 and 17, the patent outlines a method to inhibit the virus's ability to multiply within a human patient. The patent also covers the pharmaceutical compositions, meaning the specific mixtures of these chemicals with carriers that allow them to be safely delivered as medicine.

What it doesn't cover

• —Does not cover general antiviral treatments for viruses other than Hepatitis C.
• —Does not cover natural, non-synthetic chemical compounds found in nature.
• —Does not cover methods of treating HCV using different chemical scaffolds not defined by the specific formulas in the claims.
• —Does not cover medical devices or diagnostic tools for detecting the virus.

The clever bit

The innovation lies in the specific arrangement of the benzimidazolyl and heteroaryl groups, which allows the molecule to bind precisely to viral proteins, effectively shutting down the virus's replication machinery.

Why it matters

This patent is part of the intellectual property portfolio that enabled the development of highly effective direct-acting antivirals for Hepatitis C. These drugs transformed HCV from a chronic, often fatal condition into a curable disease. It represents a significant milestone in medicinal chemistry and public health.

Real-world examples

• 1.Direct-acting antiviral medications for Hepatitis C
• 2.Pharmaceutical formulations for oral HCV therapy